ADMA BIOLOGICS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $510.2M | $426.5M | $258.2M | $154.1M | $80.9M |
| Gross profit | $292.8M | $219.6M | $88.9M | $35.3M | $1.2M |
| Operating income | $191.4M | $139.0M | $21.6M | -$39.4M | -$58.4M |
| Operating expenses | $101.3M | $80.6M | $67.3M | $74.6M | $59.5M |
| Cost of revenue | $217.4M | $206.9M | $169.3M | $118.8M | $79.8M |
| Cash from operations | $50.4M | $118.7M | $8.8M | -$59.5M | -$112.4M |
| Capital expenditure | $22.6M | $8.2M | $4.8M | $13.9M | $13.5M |
| Free cash flow | $27.8M | $110.4M | $4.0M | -$73.4M | -$125.9M |
| Share repurchases | $31.9M | $0 | $0 | — | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $624.2M | $488.7M | $329.2M | $348.5M | $276.3M |
| Total liabilities | $146.9M | $139.7M | $194.0M | $196.5M | $135.1M |
Shares outstanding 231.8M · Free float 90.7%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.